Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 179 participants.

Also called NCT01278160

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 179 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01278160
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01278160. Randomized; no masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2011-09 (actual). Results posted on 2012-10-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
biphasic insulin aspart 30
Intervention (Drug)
biphasic insulin aspart 30
Intervention (Drug)
metformin
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01278160
Content hash
e67d0338432a345a7fea998f91b539772045c60c4aba892746b6d1c95c5bd517